Medivation, Inc. (MDVN) - Financial and Strategic SWOT Analysis Review

Document Sample
Medivation, Inc. (MDVN) - Financial and Strategic SWOT Analysis Review Powered By Docstoc
					               Medivation, Inc. (MDVN) - Financial and Strategic SWOT Analysis
                                            Review
        Reference Code: GDPH66457FSA                                                                                          Publication Date: APR 2012

          201 Spear Street, 3rd Floor                        Phone              +1 415 5433470                  Revenue          60.4 (million USD)
          San Francisco, CA                                  Fax                +1 415 5433411                  Net Profit       -38.84 (million USD)
          94105                                              Website            www.medivation.com              Employees        121
                                                                                                                                 Pharmaceuticals           &
          United States                                      Exchange           MDVN [NASDAQ]                   Industry
                                                                                                                                 Healthcare

       Company Overview
       Medivation, Inc. (Medivation) is a biopharmaceutical company. The company focuses on the research and development of small
       molecule drugs. The company initiates drug development programs for the development of candidates that address unmet
       medical needs such as neurological disorders and more. The company’s pipeline includes two products, namely, Dimebon for
       Alzheimer’s disease which was partnered with Pfizer and MDV3100 for Castration-Resistant, partnered with Astellas. These two
       pipeline products are in Phase III clinical trials. The company has its operation across the US. Medivation is headquartered in
       California, the US.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Medivation, Inc., SWOT Analysis
         David Hung, M.D.                    Chief Executive Officer                  Strengths                              Weaknesses
         Kim D. Blickenstaff                 Chairman
                                                                                      Agreement with Pfizer                  Lack of Product Revenues
         Daniel D. Adams                     Director
                                                                                      Focused Research and                   Weak Financial Position
         Gregory H. Bailey, M.D.             Director
                                                                                      Development Activities
         W. Anthony Vernon                   Director
        Source: Annual Report, Company Website, Primary and Secondary
        Research, GlobalData                                                          Opportunities                          Threats

       Share Data                                                                     Changing Demographics                  Stringent Government
         Medivation, Inc.                                                                                                    Regulations
                                                                                      Fast Track Status
        Share Price (USD) as on 20-Apr-                                75.06                                                 Increased Pricing Control
        2012
        EPS (USD)                                                       -1.11
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        Market Cap (million USD)                                       2,692         GlobalData

        Enterprise Value (million USD)                                 2,622
        Shares Outstanding (million)                                       36
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Feb 29, 2012         Medivation Reports Q4 2011 Results
                                                                                      Nov 17, 2011         Medivation Names Sarah Noonberg As Vice
                                                                                                           President Of Clinical Development
                                                                                      Nov 09, 2011         Medivation Reports Revenue Of $14.9m In Q3
                                                                                                           2011
                                                                                      Sep 09, 2011         Medivation Appoints Cheryl Cohen As Chief
                                                                                                           Commercial Officer


                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
       Source: Annual Report, Company Website, Primary and Secondary                 GlobalData
       Research, GlobalData




Medivation, Inc. (MDVN) - Financial and Strategic SWOT Analysis                                                                Reference Code: GDPH66457FSA
Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Medivation, Inc. - Key Facts ............................................................................................................................................................... 5
       Medivation, Inc. - Key Employees ...................................................................................................................................................... 6
       Medivation, Inc. - Key Employee Biographies .................................................................................................................................... 7
       Medivation, Inc. - Major Products and Services ................................................................................................................................. 8
       Medivation, Inc. - Pharmaceutical Pipeline Products Data ................................................................................................................. 9
          Medivation, Inc., Pipeline Products by Therapy Area ..................................................................................................................... 9
          Medivation, Inc., Pipeline Products by Development Phase ......................................................................................................... 10
       Medivation, Inc. - History .................................................................................................................................................................. 12
       Medivation, Inc. - Company Statement ............................................................................................................................................ 14
       Medivation, Inc. - Locations And Subsidiaries .................................................................................................................................. 18
          Head Office ................................................................................................................................................................................... 18
          Other Locations & Subsidiaries ..................................................................................................................................................... 18
       Section 2 – Company Analysis ......................................................................................................................................................... 19
       Medivation, Inc. - Business Description ............................................................................................................................................ 19
       Medivation, Inc. - Corporate Strategy ............................................................................................................................................... 20
       Medivation, Inc. - SWOT Analysis .................................................................................................................................................... 21
          SWOT Analysis - Overview........................................................................................................................................................... 21
          Medivation, Inc. - Strengths .......................................................................................................................................................... 21
             Strength - Agreement with Pfizer .............................................................................................................................................. 21
             Strength - Focused Research and Development Activities ....................................................................................................... 21
             Strength - Patent Portfolio ......................................................................................................................................................... 21
          Medivation, Inc. - Weaknesses ..................................................................................................................................................... 21
             Weakness - Lack of Product Revenues .................................................................................................................................... 21
             Weakness - Weak Financial Position ........................................................................................................................................ 22
             Weakness - Lack of Manufacturing Facilities ............................................................................................................................ 22
          Medivation, Inc. - Opportunities .................................................................................................................................................... 22
             Opportunity - Changing Demographics ..................................................................................................................................... 22
             Opportunity - Fast Track Status ................................................................................................................................................ 22
             Opportunity - Focus on Growing Cancer Market ....................................................................................................................... 22
             Opportunity - Collaboration With Astellas Pharma Inc............................................................................................................... 23
          Medivation, Inc. - Threats ............................................................................................................................................................. 23
             Threat - Stringent Government Regulations .............................................................................................................................. 23
             Threat - Increased Pricing Control............................................................................................................................................. 23
             Threat - Uncertain R&D outcomes ............................................................................................................................................ 23
       Medivation, Inc. - Key Competitors ................................................................................................................................................... 25
       Section 3 – Company Financial Ratios ............................................................................................................................................. 26
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 26
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 26
       Performance Chart ........................................................................................................................................................................... 27
       Financial Performance...................................................................................................................................................................... 27
       Financial Ratios - Interim Ratios....................................................................................................................................................... 28


Medivation, Inc. (MDVN) - Financial and Strategic SWOT Analysis                                                                                                Reference Code: GDPH66457FSA
Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 29
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 30
          Medivation, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012 ................................................................... 30
          Medivation, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2006 to YTD 2012 .................................................................. 31
       Medivation, Inc., Recent Deals Summary......................................................................................................................................... 32
       Section 5 – Company’s Recent Developments .......................
				
DOCUMENT INFO
Description: Medivation, Inc. (Medivation) is a biopharmaceutical company. The company focuses on the research and development of small molecule drugs. The company initiates drug development programs for the development of candidates that address unmet medical needs such as neurological disorders and more. The company’s pipeline includes two products, namely, Dimebon for Alzheimer’s disease which was partnered with Pfizer and MDV3100 for Castration-Resistant, partnered with Astellas. These two pipeline products are in Phase III clinical trials. The company has its operation across the US. Medivation is headquartered in California, the US.
BUY THIS DOCUMENT NOW PRICE: $125 100% MONEY BACK GUARANTEED
PARTNER GlobalData
GlobalData is an industry analysis specialist, providing business information products and services. GlobalData’s highly qualified team of analysts, researchers, and solution consultants use proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries. GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries. Sectors and Geographies Covered GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. Research Methodology With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries.